David Overstreet, MD
Internal Medicine · Danville, KYNPI 1659331049
Payments from drug & device makers
Across 255 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$480
- Pfizer$443
- Amgen$298
- Lilly USA, LLC$284
- AbbVie$255
- AstraZeneca$250
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,140100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $480 |
| Pfizer | 30 | $443 |
| Amgen | 19 | $298 |
| Lilly USA, LLC | 17 | $284 |
| AbbVie(2 entities) | 23 | $255 |
| AstraZeneca | 13 | $250 |
| Abbott | 13 | $222 |
| GSK | 12 | $213 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $160 |
| Sumitomo Pharma America, Inc. | 9 | $157 |
| Boehringer Ingelheim | 11 | $155 |
| Astellas Pharma US Inc | 9 | $136 |
| Kowa Pharmaceuticals America, Inc. | 6 | $115 |
| Phathom Pharmaceuticals, Inc. | 5 | $110 |
| Merck | 8 | $101 |
| Exact Sciences | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Johnson & Johnson | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 4 | $47 |
| Almatica Pharma LLC | 2 | $42 |
| Novartis | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Gilead | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$4,140 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $160,222 |
| MounjaroTirzepatide | 89 | $92,487 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $88,677 |
| IngrezzaValbenazine Tosylate | 12 | $85,848 |
| JardianceEmpagliflozin | 62 | $66,484 |
| EliquisApixaban | 67 | $56,087 |
| Ondansetron Hcl | 116 | $40,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $36,981 |
| MyrbetriqMirabegron | 59 | $32,088 |
| XareltoRivaroxaban | 41 | $26,298 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $21,954 |
| WegovySemaglutide | 17 | $21,666 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $21,620 |
| QuliptaAtogepant | 16 | $21,405 |
| FarxigaDapagliflozin Propanediol | 22 | $18,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $480 | $181,888150 claims |
| Lilly USA, LLCMounjaro | $284 | $92,48789 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $23 | $85,84812 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $155 | $72,37874 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $213 | $58,93575 claims |
| PfizerEliquis | $443 | $56,08767 claims |
| AbbVieQulipta, Ubrelvy, Creon | $255 | $45,69343 claims |
| MerckJanumet, Januvia, Dulera | $101 | $43,79145 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $32,08859 claims |
| Johnson & JohnsonXarelto | $62 | $26,29841 claims |
| AstraZenecaFarxiga, Symbicort | $250 | $25,01641 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $76 | $6,69813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Danville
- Justin LandeDanville$60K
- Tory TormaDanville$15K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.